| Parkinson Disease
Neupro vs Ongentys
Side-by-side clinical, coverage, and cost comparison for parkinson disease.Deep comparison between: Neupro vs Ongentys with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOngentys has a higher rate of injection site reactions vs Neupro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ongentys but not Neupro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Neupro
Ongentys
At A Glance
Transdermal patch
Daily
Dopamine agonist
Oral
Daily
COMT inhibitor
Indications
- Parkinson Disease
- Restless Legs Syndrome
- Parkinson Disease
Dosing
Parkinson Disease Early-stage: start 2 mg/24 hours, increase by 2 mg/24 hours weekly, max 6 mg/24 hours; advanced-stage: start 4 mg/24 hours, increase by 2 mg/24 hours weekly, max 8 mg/24 hours; applied transdermally once daily.
Restless Legs Syndrome Start 1 mg/24 hours, increase by 1 mg/24 hours weekly as needed, max 3 mg/24 hours; applied transdermally once daily.
Parkinson Disease 50 mg orally once daily at bedtime; avoid food 1 hour before and at least 1 hour after dose; reduce to 25 mg in moderate hepatic impairment (Child-Pugh B); avoid use in severe hepatic impairment (Child-Pugh C).
Contraindications
- Hypersensitivity to rotigotine or any component of the transdermal system
- Concomitant use of non-selective monoamine oxidase (MAO) inhibitors
- Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms
Adverse Reactions
Most common (>=5% above placebo) Application site reactions, nausea, somnolence, dizziness, vomiting, disturbances in initiating and maintaining sleep, peripheral edema, dyskinesia, headache, hyperhidrosis, anorexia, visual disturbance
Serious Sulfite sensitivity, falling asleep during activities of daily living, hallucinations/psychosis, symptomatic hypotension, syncope, impulse control/compulsive behaviors, elevation of blood pressure and heart rate, weight gain and fluid retention, dyskinesia, augmentation and rebound in RLS, hyperpyrexia and confusion, withdrawal symptoms, fibrotic complications
Postmarketing Withdrawal symptoms, dropped head syndrome, rhabdomyolysis
Most common (>=4%) Dyskinesia, constipation, blood creatine kinase increased, hypotension/syncope, weight decreased
Serious Cardiovascular effects with COMT-metabolized drugs, falling asleep during activities of daily living, hypotension/syncope, dyskinesia, hallucinations and psychosis, impulse control/compulsive disorders, withdrawal-emergent hyperpyrexia and confusion
Postmarketing Fall
Pharmacology
Rotigotine is a non-ergoline dopamine agonist thought to exert its therapeutic effects by stimulating dopamine receptors within the caudate-putamen in Parkinson's disease and dopamine receptors in Restless Legs Syndrome.
Opicapone is a peripheral, selective and reversible inhibitor of catechol-O-methyltransferase (COMT) that reduces levodopa breakdown to 3-OMD, thereby increasing levodopa exposure in Parkinson's disease patients treated with levodopa/carbidopa.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Neupro
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
Ongentys
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Neupro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ongentys
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (2/8) · Qty limit (1/8)
Humana
Neupro
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Ongentys
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Neupro.
No savings programs available for Ongentys.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NeuproView full Neupro profile
OngentysView full Ongentys profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.